Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more

AstraZeneca shares rose ~3% after tozorakimab meaningfully reduced COPD flare-ups in two late-stage trials; full results due at a medical meeting. Argan beat Q4 estimates with EPS $3.47 vs $1.98 expected and revenue $262.1M vs $255.3M, and Unity raised preliminary Q1 adjusted EBITDA guidance to $130–135M (prior $105–110M), sending shares sharply higher. Newsmax topped Q4 revenue at $52.2M vs $44.0M consensus and guided FY revenue $212–216M vs $206.1M expected; Tripadvisor was upgraded to buy by BofA (+3%). Bitcoin fell ~3% (two-day >6%), weighing on crypto-exposed names (Robinhood, Coinbase, Strategy down >2%), while memory names tumbled (Micron -2%, Sandisk -3%, WDC -2.3%, Lam -1.5%) and energy names rose >1% as oil moved higher.

Analysis

AstraZeneca’s positive COPD signal is a classic example where clinical headlines produce rapid re-rating but the durable value comes from payer acceptance and exacerbation-driven cost offsets. Expect regulatory filing and HTA conversations to dominate the next 12–24 months; a favorable reimbursement decision would compress COPD hospitalization rates and shave healthcare utilization, indirectly pressuring revenues of supportive acute-care providers and suppliers over 2–5 years.

Tripadvisor’s activist-driven revaluation creates real optionality: asset monetizations or focused buybacks can unlock cash within 6–12 months, but the window for meaningful multiple expansion is when visible capital returns or a strategic sale is announced. Argan’s beat signals stronger backlog conversion; key second-order risk is working-capital-driven margin swings on large turnkey projects where one or two contract delays flip quarterly operating leverage.

Unity’s outsized EBITDA beat highlights operating leverage in a fixed-cost platform business, but monetization relies on stable ad spend and developer engagement — both cyclical. Conversely, the crypto equity pullback reaffirms high beta to BTC; equities move faster and cheaper to hedge than spot crypto, creating short-term dispersion trades. Memory names still show inventory-clearing dynamics that threaten equipment OEM orderbooks (LRCX) over the next 1–3 quarters even if spot demand normalizes later.

Overall, today’s moves look like front-loaded sentiment shifts with clear near-term catalysts (activist filings, regulatory milestones, earnings cadence) and outsized reversal risk if any single catalyst disappoints. Favor option-structured exposures and pairs to capture idiosyncratic upside while protecting against binary downside outcomes over 1–18 month horizons.

Key Decisions for Investors

• Long AZN via 12–18 month call spread (buy-dated calls vs higher strike sold calls) to capture product approval/reimbursement upside; target 2–3x upside vs premium with a 20–30% max loss if negative safety/regulatory headlines emerge.
• Long TRIP equity or 6–12 month calls on any pullback into activist price range; pair with short exposure to broader online travel peers (or ETF) to isolate company-specific unlock risk; position size limited to 1–2% of portfolio until an activist filing provides a concrete timeline.
• Long AGX into any softening after the move (buy the dip), target a 20–30% upside over 6–12 months driven by backlog conversion; use a 10–15% stop or buy protective puts if quarter-over-quarter backlog growth reverses.
• Structured long on U (3–6 month call calendar or bull call spread) to play margin leverage into next dev/advertising cadence; hedge with a small short position(s) in cyclical ad-exposed names to limit macro ad-spend downside — aim for asymmetric 3:1 reward:risk.
• Hedge crypto equity exposure by buying 1–3 month puts on COIN or HOOD (or put spreads) while owning long-dated BTC calls as a convex hedge; alternatively, short shallow put spreads on LRCX/SNDK pair if memory inventory signals deteriorate further — keep position sizes small and timeboxes at 1–3 months.